Blog | Page 3 of 34 | Oncotarget

Oncotarget News

Immunotherapy Success in KRAS G12C Adenosquamous Pancreatic Cancer

November 4, 2024

Here, we present a case of metastatic ASCP with a KRAS G12C mutation refractory to multiple lines of systemic therapy, including platinum-based chemotherapy and targeted inhibition of KRAS G12C.”BUFFALO,... read more

Oncotarget

Tumor Dormancy Initiated by Lymphovascular Embolus

October 30, 2024

Both our experimental as well as observational studies indicate that in vivo lymphovascular tumor emboli and their in vitro spheroid equivalent initiate dormancy through these pathways.”BUFFALO, NY- October 30,... read more

Oncotarget

Complete Response to Encorafenib + Binimetinib in BRAF V600E-Mutant Tumor

October 29, 2024

This case report highlights the importance of full tumor genotyping to identify potentially actionable targets in rare tumors such as malignant glomus tumors.”BUFFALO, NY- October 29, 2024 – A new... read more

Drs. Mehdi Mollapour, Jennifer Heritz, and Sarah Backe

Oncotarget

Behind the Study: Molecular Chaperones & Tumor Suppressor Stability

October 24, 2024

Drs. Mehdi Mollapour, Jennifer Heritz, and Sarah Backe from SUNY Upstate Medical University (Syracuse, NY) discuss a review they co-authored that was published by Oncotarget in Volume 15, entitled “Molecular... read more

Oncotarget

How Blood Cancer Cells Rewire to Evade Drug Treatment

October 23, 2024

drugs that target individual signalling pathways in AML often fail to stop proliferation malignant growth, due to the wide variety, redundancy and cross talk between multiple pathways regulating and differentiation.”... read more